Study Supports Safety of POMELLA®

September 18, 2008

1 Min Read
Study Supports Safety of POMELLA®

NOBELSVILLE, Ind.—A new study evaluating the safety of POMELLA® Extract has been accepted in peer review by the journal Food and Chemical Toxicology.
The study concluded the no-observed-adverse-effect level (NOAEL) of POMELLA was 600 mg/kg/day—the highest dose tested—which is exponentially higher than the recommended daily dosage of POMELLA. The study tested several doses of the clinically researched, punicalagins-standardized pomegranate extract over a 90-day period.
“As one of the first systematic safety studies performed on a commercial pomegranate extract, this study breaks new ground in our long-term commitment to ensure the safety and efficacy of our products,” said Blake Ebersole, technical director of Verdure Sciences.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like